{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:29:47Z","timestamp":1787160587789,"version":"build-2736575974"},"reference-count":157,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Gastroenterol Hepatol"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1038\/s41575-026-01174-z","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T15:54:37Z","timestamp":1769788477000},"page":"355-367","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Lessons learned from viral hepatitis testing that inform law and policy responses to steatotic liver disease"],"prefix":"10.1038","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9618-2299","authenticated-orcid":false,"given":"Jeffrey V.","family":"Lazarus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Kopka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aina","family":"Nicol\u00e0s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safura Abdool","family":"Karim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7501-2191","authenticated-orcid":false,"given":"Meena B.","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Betel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2164-4476","authenticated-orcid":false,"given":"John F.","family":"Dillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4657-4504","authenticated-orcid":false,"given":"Pere","family":"Gines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9598-4932","authenticated-orcid":false,"given":"Aleksander","family":"Krag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6543-3224","authenticated-orcid":false,"given":"Veronica","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia A.","family":"Moylan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisa","family":"Pedrana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Petrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4224-4703","authenticated-orcid":false,"given":"J\u00f6rn M.","family":"Schattenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil S.","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norah","family":"Terrault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellie","family":"Dow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1854-1924","authenticated-orcid":false,"given":"Maja","family":"Thiele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,30]]},"reference":[{"key":"1174_CR1","doi-asserted-by":"publisher","DOI":"10.4414\/smw.2019.20026","volume":"149","author":"S Blach","year":"2019","unstructured":"Blach, S., Schaetti, C., Bruggmann, P., Negro, F. & Razavi, H. Cost-effectiveness analysis of strategies to manage the disease burden of hepatitis C virus in Switzerland. Swiss Med. Wkly\u00a0149, w20026 (2019).","journal-title":"Swiss Med. Wkly"},{"key":"1174_CR2","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1002\/lt.26329","volume":"28","author":"J Howell","year":"2022","unstructured":"Howell, J. et al. Turning the tide on hepatitis C virus-related liver transplantation: the return on investment in hepatitis C virus treatment in Australia and New Zealand. Liver Transpl. 28, 236\u2013246 (2022).","journal-title":"Liver Transpl."},{"key":"1174_CR3","first-page":"281","volume":"65","author":"JM Wilson","year":"1968","unstructured":"Wilson, J. M. & Jungner, Y. G. Principios y m\u00e9todos del examen colectivo para identificar enfermedades [Spanish]. Bol. Oficina Sanit. Panam. 65, 281\u2013393 (1968).","journal-title":"Bol. Oficina Sanit. Panam."},{"key":"1174_CR4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003100","volume":"17","author":"H Jarvis","year":"2020","unstructured":"Jarvis, H. et al. Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of population-based observational studies. PLoS Med. 17, e1003100 (2020).","journal-title":"PLoS Med."},{"key":"1174_CR5","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.3350\/cmh.2024.0431","volume":"31","author":"ZM Younossi","year":"2025","unstructured":"Younossi, Z. M., Kalligeros, M. & Henry, L. Epidemiology of metabolic dysfunction-associated steatotic liver disease. Clin. Mol. Hepatol. 31, S32\u2013S50 (2025).","journal-title":"Clin. Mol. Hepatol."},{"key":"1174_CR6","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/s41575-024-01022-y","volume":"22","author":"N Torp","year":"2025","unstructured":"Torp, N., Israelsen, M. & Krag, A. The steatotic liver disease burden paradox: unravelling the key role of alcohol. Nat. Rev. Gastroenterol. Hepatol. 22, 281\u2013292 (2025).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"1174_CR7","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0140-6736(21)01701-3","volume":"399","author":"TH Karlsen","year":"2022","unstructured":"Karlsen, T. H. et al. The EASL\u2013Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. Lancet 399, 61\u2013116 (2022).","journal-title":"Lancet"},{"key":"1174_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-025-00599-1","volume":"11","author":"DQ Huang","year":"2025","unstructured":"Huang, D. Q. et al. Metabolic dysfunction-associated steatotic liver disease in adults. Nat. Rev. Dis. Primers 11, 14 (2025).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"1174_CR9","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1097\/HEP.0000000000001311","volume":"83","author":"AM Allen","year":"2026","unstructured":"Allen, A. M. et al. Population perspectives on benefits and harms of screening for metabolic dysfunction-associated steatotic liver disease. Hepatology 83, 362\u2013373 (2026).","journal-title":"Hepatology"},{"key":"1174_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2025.101320","volume":"54","author":"JV Lazarus","year":"2025","unstructured":"Lazarus, J. V. et al. A call for doubling the diagnostic rate of at-risk metabolic dysfunction-associated steatohepatitis. Lancet Reg. Health Eur. 54, 101320 (2025).","journal-title":"Lancet Reg. Health Eur."},{"key":"1174_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2025.09.002","author":"ZM Younossi","year":"2025","unstructured":"Younossi, Z. M. et al. Projected global clinical, humanistic, and economic impact of metabolic dysfunction-associated steatohepatitis (MASH): the cost of inaction based on data from nine countries. Clin. Gastroenterol. Hepatol. https:\/\/doi.org\/10.1016\/j.cgh.2025.09.002 (2025).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1174_CR12","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1002\/cld.1061","volume":"17","author":"S Cheemerla","year":"2021","unstructured":"Cheemerla, S. & Balakrishnan, M. Global epidemiology of chronic liver disease. Clin. Liver Dis. 17, 365\u2013370 (2021).","journal-title":"Clin. Liver Dis."},{"key":"1174_CR13","doi-asserted-by":"crossref","unstructured":"World Health Organization. Global Hepatitis Report 2024: Action for Access in Low- and Middle-Income Countries (WHO, 2024).","DOI":"10.1007\/978-3-031-66563-9_8"},{"key":"1174_CR14","first-page":"e134","volume":"24","author":"CV Rodriguez","year":"2018","unstructured":"Rodriguez, C. V., Rubenstein, K. B., Linas, B., Hu, H. & Horberg, M. Increasing hepatitis C screening in a large integrated health system: science and policy in concert. Am. J. Managed Care 24, e134\u2013e140 (2018).","journal-title":"Am. J. Managed Care"},{"key":"1174_CR15","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1093\/cid\/ciz063","volume":"69","author":"A Chaillon","year":"2019","unstructured":"Chaillon, A., Rand, E. B., Reau, N. & Martin, N. K. Cost-effectiveness of universal hepatitis C virus screening of pregnant women in the United States. Clin. Infect. Dis. 69, 1888\u20131895 (2019).","journal-title":"Clin. Infect. Dis."},{"key":"1174_CR16","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/S2468-1253(20)30008-X","volume":"5","author":"N Scott","year":"2020","unstructured":"Scott, N. et al. A model of the economic benefits of global hepatitis C elimination: an investment case. Lancet Gastroenterol. Hepatol. 5, 940\u2013947 (2020).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"1174_CR17","volume":"18","author":"N Scott","year":"2021","unstructured":"Scott, N. et al. Assessment of the cost-effectiveness of Australia\u2019s risk-sharing agreement for direct-acting antiviral treatments for hepatitis C: a modelling study. Lancet Reg. Health West. Pac. 18, 100316 (2021).","journal-title":"Lancet Reg. Health West. Pac."},{"key":"1174_CR18","doi-asserted-by":"publisher","first-page":"S180","DOI":"10.1093\/infdis\/jiad016","volume":"228","author":"RN Chien","year":"2023","unstructured":"Chien, R. N. et al. Policy and strategy for hepatitis C virus elimination at the national level: experience in Taiwan. J. Infect. Dis. 228, S180\u2013S188 (2023).","journal-title":"J. Infect. Dis."},{"key":"1174_CR19","doi-asserted-by":"publisher","first-page":"293","DOI":"10.35772\/ghm.2021.01064","volume":"3","author":"RN Chien","year":"2021","unstructured":"Chien, R. N. et al. Taiwan accelerates its efforts to eliminate hepatitis C. Glob. Health Med. 3, 293\u2013300 (2021).","journal-title":"Glob. Health Med."},{"key":"1174_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s41124-018-0033-8","volume":"3","author":"JM Delile","year":"2018","unstructured":"Delile, J. M. et al. Hepatitis C virus prevention and care for drug injectors: the French approach. Hepatol. Med. Policy 3, 7 (2018).","journal-title":"Hepatol. Med. Policy"},{"key":"1174_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/v16050792","volume":"16","author":"C Brouard","year":"2024","unstructured":"Brouard, C. et al. Impact of public policy and COVID-19 pandemic on hepatitis C testing and treatment in France, 2014\u20132021. Viruses\u00a016, 792 (2024).","journal-title":"Viruses"},{"key":"1174_CR22","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1111\/liv.14222","volume":"39","author":"SE Schr\u00f6eder","year":"2019","unstructured":"Schr\u00f6eder, S. E. et al. Innovative strategies for the elimination of viral hepatitis at a national level: a country case series. Liver Int. 39, 1818\u20131836 (2019).","journal-title":"Liver Int."},{"key":"1174_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-021-11608-9","volume":"21","author":"D Busschots","year":"2021","unstructured":"Busschots, D. et al. On-site testing and case management to improve hepatitis C care in drug users: a prospective, longitudinal, multicenter study in the DAA era. BMC Public Health 21, 1574 (2021).","journal-title":"BMC Public Health"},{"key":"1174_CR24","doi-asserted-by":"publisher","first-page":"S204","DOI":"10.1093\/infdis\/jiad022","volume":"228","author":"H Qureshi","year":"2023","unstructured":"Qureshi, H., Mahmood, H., Sabry, A. & Hermez, J. Barriers and strategies for hepatitis B and C elimination in Pakistan. J. Infect. Dis. 228, S204\u2013S210 (2023).","journal-title":"J. Infect. Dis."},{"key":"1174_CR25","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1177\/00333549161310S211","volume":"131","author":"C Coyle","year":"2016","unstructured":"Coyle, C., Kwakwa, H. & Viner, K. Integrating routine HCV testing in primary care: lessons learned from five federally qualified health centers in Philadelphia, Pennsylvania, 2012\u20132014. Public Health Rep. 131, 65\u201373 (2016).","journal-title":"Public Health Rep."},{"key":"1174_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-023-00831-9","volume":"20","author":"SN Kapadia","year":"2023","unstructured":"Kapadia, S. N. et al. \u201cTreated like a Human Being\u201d: perspectives of people who inject drugs attending low-threshold HCV treatment at a syringe service program in New York City. Harm Reduct. J. 20, 95 (2023).","journal-title":"Harm Reduct. J."},{"key":"1174_CR27","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1111\/jvh.13360","volume":"27","author":"R Irvin","year":"2020","unstructured":"Irvin, R. et al. Sharing the cure: building primary care and public health infrastructure to improve the hepatitis C care continuum in Maryland. J. Viral Hepat. 27, 1388\u20131395 (2020).","journal-title":"J. Viral Hepat."},{"key":"1174_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0210556","volume":"14","author":"A Mane","year":"2019","unstructured":"Mane, A. et al. Evaluation of five rapid diagnostic tests for detection of antibodies to hepatitis C virus (HCV): a step towards scale-up of HCV screening efforts in India. PLoS ONE 14, e0210556 (2019).","journal-title":"PLoS ONE"},{"key":"1174_CR29","unstructured":"World Health Organization. Hepatitis C https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c (WHO, 2025)."},{"key":"1174_CR30","unstructured":"World Health Organization. WHO Sounds Alarm on Viral Hepatitis Infections Claiming 3500 Lives Each Day https:\/\/www.who.int\/news\/item\/09-04-2024-who-sounds-alarm-on-viral-hepatitis-infections-claiming-3500-lives-each-day (WHO, 2024)."},{"key":"1174_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12030288","volume":"12","author":"SA Al-Busafi","year":"2024","unstructured":"Al-Busafi, S. A. & Alwassief, A. Global perspectives on the hepatitis B vaccination: challenges, achievements, and the road to elimination by 2030. Vaccines 12, 288 (2024).","journal-title":"Vaccines"},{"key":"1174_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12111254","volume":"12","author":"A Dom\u00ednguez","year":"2024","unstructured":"Dom\u00ednguez, A. et al. Hepatitis B virus-related cirrhosis and hepatocellular carcinoma hospital discharge rates from 2005 to 2021 in Spain: impact of universal vaccination. Vaccines 12, 1254 (2024).","journal-title":"Vaccines"},{"key":"1174_CR33","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S2468-1253(22)00124-8","volume":"7","author":"GBD 2019 Hepatitis B Collaborators","year":"2022","unstructured":"GBD 2019 Hepatitis B Collaborators Global, regional, and national burden of hepatitis B, 1990-2019: a systematic analysis for the global burden of disease study 2019. Lancet Gastroenterol. Hepatol. 7, 796\u2013829 (2022).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"1174_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s12939-024-02209-0","volume":"23","author":"G Fontaine","year":"2024","unstructured":"Fontaine, G. et al. Using an intersectionality lens to explore barriers and enablers to hepatitis C point-of-care testing: a qualitative study among people who inject drugs and service providers. Int. J. Equity Health 23, 124 (2024).","journal-title":"Int. J. Equity Health"},{"key":"1174_CR35","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1111\/jvh.13119","volume":"26","author":"AH Litwin","year":"2019","unstructured":"Litwin, A. H. et al. Perceived barriers related to testing, management and treatment of HCV infection among physicians prescribing opioid agonist therapy: the C-SCOPE study. J. Viral Hepat. 26, 1094\u20131104 (2019).","journal-title":"J. Viral Hepat."},{"key":"1174_CR36","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.jhep.2019.05.033","volume":"71","author":"JF Dillon","year":"2019","unstructured":"Dillon, J. F. et al. Intelligent liver function testing (iLFT): a trial of automated diagnosis and staging of liver disease in primary care. J. Hepatol. 71, 699\u2013706 (2019).","journal-title":"J. Hepatol."},{"key":"1174_CR37","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1002\/hep.27654","volume":"61","author":"B Suh","year":"2015","unstructured":"Suh, B. et al. High liver fibrosis index FIB-4 is highly predictive of hepatocellular carcinoma in chronic hepatitis B carriers. Hepatology. 61, 1261\u20131268 (2015).","journal-title":"Hepatology."},{"key":"1174_CR38","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1002\/hep.30979","volume":"71","author":"L Asphaug","year":"2020","unstructured":"Asphaug, L., Thiele, M., Krag, A. & Melberg, H. O. Cost-effectiveness of noninvasive screening for alcohol-related liver fibrosis. Hepatology. 71, 2093\u20132104 (2020).","journal-title":"Hepatology."},{"key":"1174_CR39","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/S2468-1253(25)00097-4","volume":"10","author":"S Johansen","year":"2025","unstructured":"Johansen, S. et al. Screening for advanced steatotic liver disease. Lancet Gastroenterol. Hepatol. 10, 842\u2013854 (2025).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"1174_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s43856-025-00796-9","volume":"5","author":"E Shumbayawonda","year":"2025","unstructured":"Shumbayawonda, E. et al. Utility and cost-effectiveness of LiverMultiScan for MASLD diagnosis: a real-world multi-national randomised clinical trial. Commun. Med. 5, 74 (2025).","journal-title":"Commun. Med."},{"key":"1174_CR41","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.cgh.2018.05.057","volume":"17","author":"Z Younossi","year":"2019","unstructured":"Younossi, Z. et al. Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates. Clin. Gastroenterol. Hepatol. 17, 748\u2013755.e3 (2019).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1174_CR42","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.cgh.2023.05.019","volume":"22","author":"JH Koh","year":"2024","unstructured":"Koh, J. H. et al. NASH is the leading cause of hepatocellular carcinoma in liver transplant candidates. Clin. Gastroenterol. Hepatol. 22, 197\u2013199.e3 (2024).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1174_CR43","doi-asserted-by":"publisher","first-page":"S313","DOI":"10.1093\/infdis\/jiae127","volume":"229","author":"S Kamili","year":"2024","unstructured":"Kamili, S. & Wester, C. Advancing diagnosis of current hepatitis C virus infection: a key to hepatitis C elimination in the United States. J. Infect. Dis. 229, S313\u2013S315 (2024).","journal-title":"J. Infect. Dis."},{"key":"1174_CR44","doi-asserted-by":"publisher","first-page":"S328","DOI":"10.1093\/infdis\/jiad269","volume":"229","author":"K Page","year":"2024","unstructured":"Page, K. & Feinberg, J. What hepatitis C virus (HCV) diagnostic tools are needed to advance diagnosis of current HCV infection in outreach settings and in a nonclinical setting? J. Infect. Dis. 229, S328\u2013S333 (2024).","journal-title":"J. Infect. Dis."},{"key":"1174_CR45","doi-asserted-by":"publisher","first-page":"S342","DOI":"10.1093\/infdis\/jiad463","volume":"229","author":"E Ivanova Reipold","year":"2024","unstructured":"Ivanova Reipold, E., Shilton, S., Donolato, M. & Fernandez Suarez, M. Molecular point-of-care testing for hepatitis C: available technologies, pipeline, and promising future directions. J. Infect. Dis. 229, S342\u2013S349 (2024).","journal-title":"J. Infect. Dis."},{"key":"1174_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fviro.2021.742722","volume":"1","author":"JA Shenge","year":"2021","unstructured":"Shenge, J. A. & Osiowy, C. Rapid diagnostics for hepatitis B and C viruses in low-and middle-income countries. Front. Virol. 1, 742722 (2021).","journal-title":"Front. Virol."},{"key":"1174_CR47","doi-asserted-by":"publisher","first-page":"S69","DOI":"10.1016\/j.japh.2018.04.031","volume":"58","author":"A Brewer","year":"2018","unstructured":"Brewer, A., Hanna, C., Eckmann, L., Schadler, A. & Divine, H. Patient awareness, willingness, and barriers to point-of-care hepatitis C screening in community pharmacy. J. Am. Pharm. Assoc. 58, S69\u2013S72.e1 (2018).","journal-title":"J. Am. Pharm. Assoc."},{"key":"1174_CR48","doi-asserted-by":"publisher","first-page":"eS180","DOI":"10.21815\/JDE.017.025","volume":"81","author":"M Glick","year":"2017","unstructured":"Glick, M. & Greenberg, B. L. The role of oral health care professionals in providing medical services. J. Dent. Educ. 81, eS180\u2013eS185 (2017).","journal-title":"J. Dent. Educ."},{"key":"1174_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-023-09777-x","volume":"23","author":"MA Corcorran","year":"2023","unstructured":"Corcorran, M. A., Scott, J. D., Naveira, M. & Easterbrook, P. Training the healthcare workforce to support task-shifting and viral hepatitis elimination: a global review of English language online trainings and in-person workshops for management of hepatitis B and C infection. BMC Health Serv. Res. 23, 849 (2023).","journal-title":"BMC Health Serv. Res."},{"key":"1174_CR50","doi-asserted-by":"publisher","first-page":"e431","DOI":"10.1016\/S2214-109X(20)30505-2","volume":"9","author":"E Oru","year":"2021","unstructured":"Oru, E., Trickey, A., Shirali, R., Kanters, S. & Easterbrook, P. Decentralisation, integration, and task-shifting in hepatitis C virus infection testing and treatment: a global systematic review and meta-analysis. Lancet Glob. Health 9, e431\u2013e445 (2021).","journal-title":"Lancet Glob. Health"},{"key":"1174_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2020.102755","volume":"80","author":"J Broad","year":"2020","unstructured":"Broad, J. et al. Peer outreach point-of-care testing as a bridge to hepatitis C care for people who inject drugs in Toronto, Canada. Int. J. Drug Policy 80, 102755 (2020).","journal-title":"Int. J. Drug Policy"},{"key":"1174_CR52","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3138\/canlivj-2023-0016","volume":"7","author":"M Selfridge","year":"2024","unstructured":"Selfridge, M. et al. \u2018I just never wanted them to feel uncomfortable\u2019: barriers to pharmacy-based identification and treatment of hepatitis C in Victoria, Canada. Can. Liver J. 7, 257\u2013272 (2024).","journal-title":"Can. Liver J."},{"key":"1174_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics11030463","volume":"11","author":"M Majam","year":"2021","unstructured":"Majam, M. et al. A lay-user assessment of hepatitis C virus self-testing device usability and interpretation in Johannesburg, South Africa. Diagnostics\u00a011, 463 (2021).","journal-title":"Diagnostics"},{"key":"1174_CR54","unstructured":"World Health Organization. WHO Prequalifies the First Self-Test for Hepatitis C Virus https:\/\/www.who.int\/news\/item\/10-07-2024-who-prequalifies-the-first-self-test-for-hepatitis-c-virus#:~:Text=WHO%20recommended%20HCV%20self%2Dtesting,who%20may%20not%20otherwise%20test (WHO, 2024)."},{"key":"1174_CR55","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1097\/HEP.0000000000000842","volume":"81","author":"K Patel","year":"2025","unstructured":"Patel, K. et al. Accuracy of blood-based biomarkers for staging liver fibrosis in chronic liver disease: a systematic review supporting the AASLD Practice Guideline. Hepatology. 81, 358\u2013379 (2025).","journal-title":"Hepatology."},{"key":"1174_CR56","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","volume":"77","author":"H Rumgay","year":"2022","unstructured":"Rumgay, H. et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 77, 1598\u20131606 (2022).","journal-title":"J Hepatol."},{"key":"1174_CR57","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.cgh.2023.12.018","volume":"22","author":"M Kjaergaard","year":"2024","unstructured":"Kjaergaard, M. et al. Screening for fibrosis promotes lifestyle changes: a prospective cohort study in 4796 individuals. Clin. Gastroenterol. Hepatol. 22, 1037\u20131047.e9 (2024).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1174_CR58","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1111\/liv.15209","volume":"42","author":"P Carrieri","year":"2022","unstructured":"Carrieri, P. et al. Knowledge of liver fibrosis stage among adults with NAFLD\/NASH improves adherence to lifestyle changes. Liver Int. 42, 984\u2013994 (2022).","journal-title":"Liver Int."},{"key":"1174_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101165","volume":"6","author":"E Avitabile","year":"2024","unstructured":"Avitabile, E. et al. Liver fibrosis screening increases alcohol abstinence. JHEP Rep. 6, 101165 (2024).","journal-title":"JHEP Rep."},{"key":"1174_CR60","doi-asserted-by":"publisher","DOI":"10.1111\/liv.70390","volume":"45","author":"JV Lazarus","year":"2025","unstructured":"Lazarus, J. V. et al. Cost of metabolic dysfunction-associated steatotic liver disease screening among all people living with diabetes in six countries. Liver Int. 45, e70390 (2025).","journal-title":"Liver Int."},{"key":"1174_CR61","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1093\/milmed\/usae273","volume":"190","author":"DC Kelly","year":"2025","unstructured":"Kelly, D. C. & Webber, B. Review of the U.S. Air Force Academy hepatitis C virus screening program to ensure high-value care. Mil. Med. 190, e11\u2013e14 (2025).","journal-title":"Mil. Med."},{"key":"1174_CR62","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-018-0246-6","volume":"15","author":"L Lafferty","year":"2018","unstructured":"Lafferty, L., Cameron Wild, T., Rance, J. & Treloar, C. A policy analysis exploring hepatitis C risk, prevention, testing, treatment and reinfection within Australia\u2019s prisons. Harm Reduct. J. 15, 39 (2018).","journal-title":"Harm Reduct. J."},{"key":"1174_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2022.103837","volume":"109","author":"AS Ruiz","year":"2022","unstructured":"Ruiz, A. S. et al. Identifying barriers and enablers to opt-out hepatitis C virus screening in provincial prisons in Quebec, Canada: a multilevel, multi-theory informed qualitative study with correctional and healthcare professional stakeholders. Int. J. Drug Policy 109, 103837 (2022).","journal-title":"Int. J. Drug Policy"},{"key":"1174_CR64","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-018-0269-z","volume":"15","author":"D Crowley","year":"2018","unstructured":"Crowley, D. et al. Barriers and facilitators to hepatitis C (HCV) screening and treatment \u2014 a description of prisoners\u2019 perspective. Harm Reduct. J. 15, 62 (2018).","journal-title":"Harm Reduct. J."},{"key":"1174_CR65","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1097\/QAI.0000000000001664","volume":"78","author":"W Ly","year":"2018","unstructured":"Ly, W. et al. Perspectives on Integrated HIV and hepatitis C virus testing among persons entering a Northern California jail: a pilot study. J. Acquir. Immune Defic. Syndr. 78, 214\u2013220 (2018).","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"1174_CR66","unstructured":"National Health Service. Screening for Hepatitis B, HIV and Syphilis. https:\/\/www.nhs.uk\/pregnancy\/your-pregnancy-care\/screening-for-hepatitis-b-hiv-and-syphilis\/ (NHS, 2024)."},{"key":"1174_CR67","unstructured":"Department of Health. Are You Screening for Hepatitis A at Each Pregnancy? https:\/\/www.health.ny.gov\/diseases\/communicable\/hepatitis\/hepatitis_c\/testing\/providers.htm#:~:Text=Effective%20May%203%2C%202024%2C%20New,at%20any%20time%20during%20pregnancy (New York State, 2024)."},{"key":"1174_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2023.104185","volume":"121","author":"J Demant","year":"2023","unstructured":"Demant, J. et al. Peer-delivered point-of-care testing and linkage to treatment for hepatitis C virus infection among marginalized populations through a mobile clinic in Copenhagen, Denmark. Int. J. Drug Policy 121, 104185 (2023).","journal-title":"Int. J. Drug Policy"},{"key":"1174_CR69","doi-asserted-by":"publisher","first-page":"v39","DOI":"10.1093\/jac\/dkz455","volume":"74","author":"S Barror","year":"2019","unstructured":"Barror, S. et al. HepCare Europe: a service innovation project. HepCheck: enhancing HCV identification and linkage to care for vulnerable populations through intensified outreach screening. A prospective multisite feasibility study. J. Antimicrob. Chemother. 74, v39\u2013v46 (2019).","journal-title":"J. Antimicrob. Chemother."},{"key":"1174_CR70","volume":"51","author":"S Tillakeratne","year":"2024","unstructured":"Tillakeratne, S. et al. Trends in viral hepatitis liver-related morbidity and mortality in New South Wales, Australia. Lancet Reg. Health West Pac. 51, 101185 (2024).","journal-title":"Lancet Reg. Health West Pac."},{"key":"1174_CR71","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3138\/canlivj.2019-0002","volume":"3","author":"MJ Biondi","year":"2020","unstructured":"Biondi, M. J. & Feld, J. J. Hepatitis C models of care: approaches to elimination. Can. Liver J. 3, 165\u2013176 (2020).","journal-title":"Can. Liver J."},{"key":"1174_CR72","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2023.1118227","volume":"11","author":"CPB Moonen","year":"2023","unstructured":"Moonen, C. P. B. et al. A systematic review of barriers and facilitators for hepatitis B and C screening among migrants in the EU\/EEA region. Front. Public Health 11, 1118227 (2023).","journal-title":"Front. Public Health"},{"key":"1174_CR73","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgph.0002436","volume":"3","author":"C Brown","year":"2023","unstructured":"Brown, C. et al. Exploring the limitations of language interpretation: a qualitative study on clinicians\u2019 experiences at French Office of Immigration and Integration. PLoS Glob. Public Health 3, e0002436 (2023).","journal-title":"PLoS Glob. Public Health"},{"key":"1174_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101145","volume":"6","author":"A Herranz Mochales","year":"2024","unstructured":"Herranz Mochales, A. et al. Implementing a new HCV model of care for people who use drugs. JHEP Rep. 6, 101145 (2024).","journal-title":"JHEP Rep."},{"key":"1174_CR75","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12237276","volume":"12","author":"J Rivera-Esteban","year":"2023","unstructured":"Rivera-Esteban, J. et al. Prevalence and risk factors of MASLD and liver fibrosis amongst the penitentiary population in Catalonia: the PRISONAFLD study. J Clin Med 12, 7276 (2023).","journal-title":"J Clin Med"},{"key":"1174_CR76","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.54707","volume":"8","author":"P Le","year":"2025","unstructured":"Le, P. et al. Estimated burden of metabolic dysfunction-associated steatotic liver disease in US adults, 2020 to 2050. JAMA Netw. Open 8, e2454707 (2025).","journal-title":"JAMA Netw. Open"},{"key":"1174_CR77","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1038\/s41591-024-02958-z","volume":"30","author":"JV Lazarus","year":"2024","unstructured":"Lazarus, J. V. et al. Opportunities and challenges following approval of resmetirom for MASH liver disease. Nat. Med. 30, 3402\u20133405 (2024).","journal-title":"Nat. Med."},{"key":"1174_CR78","doi-asserted-by":"publisher","DOI":"10.1186\/s13104-015-1719-2","volume":"8","author":"T Birku","year":"2015","unstructured":"Birku, T., Gelaw, B., Moges, F. & Assefa, A. Prevalence of hepatitis B and C viruses infection among military personnel at Bahir Dar Armed Forces General Hospital, Ethiopia. BMC Res. Notes 8, 737 (2015).","journal-title":"BMC Res. Notes"},{"key":"1174_CR79","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1097\/PHH.0000000000000519","volume":"24","author":"MM Ford","year":"2018","unstructured":"Ford, M. M. et al. Check Hep C: a community-based approach to hepatitis C diagnosis and linkage to care in high-risk populations. J. Public Health Manag. Pract. 24, 41\u201348 (2018).","journal-title":"J. Public Health Manag. Pract."},{"key":"1174_CR80","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1111\/jvh.12809","volume":"25","author":"V Saludes","year":"2018","unstructured":"Saludes, V. et al. Community-based screening of hepatitis C with a one-step RNA detection algorithm from dried-blood spots: analysis of key populations in Barcelona, Spain. J. Viral Hepat. 25, 236\u2013244 (2018).","journal-title":"J. Viral Hepat."},{"key":"1174_CR81","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgph.0001667","volume":"3","author":"JG Walker","year":"2023","unstructured":"Walker, J. G. et al. Cost-effectiveness of hepatitis C virus self-testing in four settings. PLoS Glob. Public Health 3, e0001667 (2023).","journal-title":"PLoS Glob. Public Health"},{"key":"1174_CR82","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000678","volume":"9","author":"AM Allen","year":"2025","unstructured":"Allen, A. M. et al. Global patterns of utilization of noninvasive tests for the clinical management of metabolic dysfunction-associated steatotic liver disease. Hepatol. Commun. 9, e0678 (2025).","journal-title":"Hepatol. Commun."},{"key":"1174_CR83","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","volume":"81","author":"European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO)","year":"2024","unstructured":"European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO) EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J. Hepatol. 81, 492\u2013542 (2024).","journal-title":"J. Hepatol."},{"key":"1174_CR84","unstructured":"Polonord Adeste. Test Fegato https:\/\/polonordadeste.com\/Test-Fegato-p532637066 (Polonord Adeste, accessed in 2025)."},{"key":"1174_CR85","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1111\/liv.15951","volume":"44","author":"CJ Kopka","year":"2024","unstructured":"Kopka, C. J., Pugliese, N., Brennan, P. N. & Lazarus, J. V. We must address the MASLD awareness gap, improve educational quality and prepare for the digitally quantified self. Liver Int. 44, 2099\u20132101 (2024).","journal-title":"Liver Int."},{"key":"1174_CR86","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2023.103982","volume":"114","author":"J Grebely","year":"2023","unstructured":"Grebely, J. et al. Single-visit hepatitis C point-of-care testing, linkage to nursing care, and peer-supported treatment among people with recent injecting drug use at a peer-led needle and syringe program: the TEMPO pilot study. Int. J. Drug Policy 114, 103982 (2023).","journal-title":"Int. J. Drug Policy"},{"key":"1174_CR87","doi-asserted-by":"publisher","DOI":"10.1038\/s43856-023-00420-8","volume":"3","author":"CA Picchio","year":"2023","unstructured":"Picchio, C. A. et al. Community-based screening enhances hepatitis B virus linkage to care among West African migrants in Spain. Commun. Med. 3, 182 (2023).","journal-title":"Commun. Med."},{"key":"1174_CR88","doi-asserted-by":"publisher","first-page":"234","DOI":"10.3138\/canlivj-2022-0029","volume":"6","author":"E Mandel","year":"2023","unstructured":"Mandel, E. et al. Province-to-province variability in hepatitis C testing, care, and treatment across Canada. Can. Liver J. 6, 234\u2013248 (2023).","journal-title":"Can. Liver J."},{"key":"1174_CR89","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.jval.2020.03.014","volume":"23","author":"J Williams","year":"2020","unstructured":"Williams, J. et al. An economic evaluation of the cost-effectiveness of opt-out hepatitis B and hepatitis C testing in an emergency department setting in the United Kingdom. Value Health 23, 1003\u20131011 (2020).","journal-title":"Value Health"},{"key":"1174_CR90","doi-asserted-by":"publisher","first-page":"v17","DOI":"10.1093\/jac\/dkz452","volume":"74","author":"J Surey","year":"2019","unstructured":"Surey, J. et al. From peer-based to peer-led: redefining the role of peers across the hepatitis C care pathway: HepCare Europe. J Antimicrob. Chemother. 74, v17\u2013v23 (2019).","journal-title":"J Antimicrob. Chemother."},{"key":"1174_CR91","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.jinf.2022.09.021","volume":"85","author":"G Myring","year":"2022","unstructured":"Myring, G. et al. Cost-effectiveness of pharmacy-led versus conventionally delivered antiviral treatment for hepatitis C in patients receiving opioid substitution therapy: an economic evaluation alongside a pragmatic cluster randomised trial. J. Infect. 85, 676\u2013682 (2022).","journal-title":"J. Infect."},{"key":"1174_CR92","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","volume":"77","author":"ME Rinella","year":"2023","unstructured":"Rinella, M. E. et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology 77, 1797\u20131835 (2023).","journal-title":"Hepatology"},{"key":"1174_CR93","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.2337\/dci24-0094","volume":"48","author":"K Cusi","year":"2025","unstructured":"Cusi, K. et al. Metabolic dysfunction-associated steatotic liver disease (MASLD) in people with diabetes: the need for screening and early intervention. A consensus report of the American Diabetes Association. Diabetes Care 48, 1057\u20131082 (2025).","journal-title":"Diabetes Care"},{"key":"1174_CR94","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","volume":"28","author":"K Cusi","year":"2022","unstructured":"Cusi, K. et al. American Association of Clinical Endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: co-sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr. Pract. 28, 528\u2013562 (2022).","journal-title":"Endocr. Pract."},{"key":"1174_CR95","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2025.101903","volume":"30","author":"LA Diaz","year":"2025","unstructured":"Diaz, L. A. et al. Updated recommendations for the management of metabolic dysfunction-associated steatotic liver disease (MASLD) by the Latin American working group. Ann. Hepatol. 30, 101903 (2025).","journal-title":"Ann. Hepatol."},{"key":"1174_CR96","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s12072-024-10774-3","volume":"19","author":"M Eslam","year":"2025","unstructured":"Eslam, M. et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease. Hepatol. Int. 19, 261\u2013301 (2025).","journal-title":"Hepatol. Int."},{"key":"1174_CR97","unstructured":"American Association of Clinical Endocrinology. AACE Patient Guide to Metabolic Dysfunction\u2013Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction\u2013Associated Steatohepatitis (MASH) https:\/\/www.aace.com\/disease-and-conditions\/masldmash\/aace-patient-guide-masld-mash (AACE, 2025."},{"key":"1174_CR98","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/S2468-1253(25)00187-6","volume":"10","author":"N Torp","year":"2025","unstructured":"Torp, N. et al. Phosphatidylethanol and self-reported alcohol intake to subclassify individuals at risk of steatotic liver disease: an analysis of data from a prospective cohort study. Lancet Gastroenterol. Hepatol. 10, 975\u2013985 (2025).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"1174_CR99","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1016\/S0140-6736(24)01811-7","volume":"404","author":"M Israelsen","year":"2024","unstructured":"Israelsen, M., Francque, S., Tsochatzis, E. A. & Krag, A. Steatotic liver disease. Lancet. 404, 1761\u20131778 (2024).","journal-title":"Lancet."},{"key":"1174_CR100","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1056\/NEJMra2403308","volume":"393","author":"L Castera","year":"2025","unstructured":"Castera, L., Rinella, M. E. & Tsochatzis, E. A. Noninvasive assessment of liver fibrosis. N. Engl. J. Med. 393, 1715\u20131729 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1174_CR101","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanmic.2024.100979","volume":"5","author":"P Venkatesan","year":"2024","unstructured":"Venkatesan, P. First self-test for hepatitis C virus. Lancet Microbe 5, 100979 (2024).","journal-title":"Lancet Microbe"},{"key":"1174_CR102","unstructured":"US Food and Drug Administration. Direct-to-consumer tests https:\/\/www.fda.gov\/medical-devices\/in-vitro-diagnostics\/direct-consumer-tests (FDA, 2019)."},{"key":"1174_CR103","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s12687-022-00582-3","volume":"13","author":"A Cernat","year":"2022","unstructured":"Cernat, A., Bashir, N. S. & Ungar, W. J. Considerations for developing regulations for direct-to-consumer genetic testing: a scoping review using the 3-I framework. J. Community Genet. 13, 155\u2013170 (2022).","journal-title":"J. Community Genet."},{"key":"1174_CR104","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhealeco.2021.102549","volume":"81","author":"D Dranove","year":"2022","unstructured":"Dranove, D., Garthwaite, C., Heard, C. & Wu, B. The economics of medical procedure innovation. J. Health Econ. 81, 102549 (2022).","journal-title":"J. Health Econ."},{"key":"1174_CR105","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.jpubeco.2016.11.010","volume":"145","author":"AD Stern","year":"2017","unstructured":"Stern, A. D. Innovation under regulatory uncertainty: evidence from medical technology. J. Public Econ. 145, 181\u2013200 (2017).","journal-title":"J. Public Econ."},{"key":"1174_CR106","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13040684","volume":"13","author":"E Duah","year":"2023","unstructured":"Duah, E., Mathebula, E. M. & Mashamba-Thompson, T. Quality assurance for hepatitis C virus point-of-care diagnostics in sub-Saharan Africa. Diagnostics\u00a013, 684 (2023).","journal-title":"Diagnostics"},{"key":"1174_CR107","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/jvh.12827","volume":"25","author":"L Duchesne","year":"2018","unstructured":"Duchesne, L. & Lacombe, K. Innovative technologies for point-of-care testing of viral hepatitis in low-resource and decentralized settings. J. Viral Hepat. 25, 108\u2013117 (2018).","journal-title":"J. Viral Hepat."},{"key":"1174_CR108","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1080\/14737159.2023.2292645","volume":"24","author":"J Grebely","year":"2024","unstructured":"Grebely, J. et al. We have reached single-visit testing, diagnosis, and treatment for hepatitis C infection, now what? Expert Rev. Mol. Diagn. 24, 177\u2013191 (2024).","journal-title":"Expert Rev. Mol. Diagn."},{"key":"1174_CR109","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1038\/s41551-022-00935-w","volume":"6","author":"G Ahmed","year":"2022","unstructured":"Ahmed, G. & Mahfouz, M. Straightforward, inexpensive and sensitive. Nat. Biomed. Eng. 6, 923\u2013924 (2022).","journal-title":"Nat. Biomed. Eng."},{"key":"1174_CR110","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14090960","volume":"14","author":"J Nobes","year":"2024","unstructured":"Nobes, J., Leith, D., Handjiev, S., Dillon, J. F. & Dow, E. Intelligent liver function testing (iLFT): An intelligent laboratory approach to identifying chronic liver disease. Diagnostics\u00a014, 960 (2024).","journal-title":"Diagnostics"},{"key":"1174_CR111","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2025.120269","volume":"572","author":"M Plebani","year":"2025","unstructured":"Plebani, M. & Abdurrahman, C. Promoting value-based laboratory medicine: moving towards an innovative model of clinical laboratory. Clin. Chim. Acta 572, 120269 (2025).","journal-title":"Clin. Chim. Acta"},{"key":"1174_CR112","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3138\/canlivj-2022-0040","volume":"6","author":"G Snell","year":"2023","unstructured":"Snell, G. et al. Public reimbursement policies in Canada for direct-acting antiviral treatment of hepatitis C virus infection: a descriptive study. Can. Liver J. 6, 190\u2013200 (2023).","journal-title":"Can. Liver J."},{"key":"1174_CR113","doi-asserted-by":"publisher","first-page":"270","DOI":"10.35772\/ghm.2021.01080","volume":"3","author":"X Mei","year":"2021","unstructured":"Mei, X. & Lu, H. Prevalence, diagnosis, and treatment of hepatitis C in mainland China. Glob. Health Med. 3, 270\u2013275 (2021).","journal-title":"Glob. Health Med."},{"key":"1174_CR114","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.antiviral.2017.12.001","volume":"150","author":"H Leblebicioglu","year":"2018","unstructured":"Leblebicioglu, H. et al. Availability of hepatitis C diagnostics and therapeutics in European and Eurasia countries. Antiviral Res. 150, 9\u201314 (2018).","journal-title":"Antiviral Res."},{"key":"1174_CR115","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.109092","volume":"228","author":"G Pro","year":"2021","unstructured":"Pro, G., Tompkins, D. A., Azari, S. & Zaller, N. National trends in testing for hepatitis C virus in licensed opioid treatment programs: differences by facility ownership and state medicaid expansion status. Drug Alcohol Depend. 228, 109092 (2021).","journal-title":"Drug Alcohol Depend."},{"key":"1174_CR116","doi-asserted-by":"publisher","first-page":"308","DOI":"10.35772\/ghm.2021.01072","volume":"3","author":"M Korenaga","year":"2021","unstructured":"Korenaga, M. & Kanto, T. Testing, diagnosis of viral hepatitis, and the follow-up policy in Japan. Glob. Health Med. 3, 308\u2013313 (2021).","journal-title":"Glob. Health Med."},{"key":"1174_CR117","unstructured":"Rawat, V. et al. in Issues on Health Science (eds Sreenivasan, A. et al.) 117\u2013135 (ZenToks, 2025)."},{"key":"1174_CR118","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-024-01117-4","volume":"21","author":"B Zovich","year":"2024","unstructured":"Zovich, B. et al. Identifying barriers to hepatitis B and delta screening, prevention, and linkage to care among people who use drugs in Philadelphia, Pennsylvania, USA. Harm Reduct. J. 21, 199 (2024).","journal-title":"Harm Reduct. J."},{"key":"1174_CR119","doi-asserted-by":"publisher","first-page":"36","DOI":"10.18773\/austprescr.2021.003","volume":"44","author":"GJ Dore","year":"2021","unstructured":"Dore, G. J. Elimination of hepatitis C in Australia by 2030: a decade and counting. Aust. Prescr. 44, 36\u201337 (2021).","journal-title":"Aust. Prescr."},{"key":"1174_CR120","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-018-1162-z","volume":"16","author":"CH Douglass","year":"2018","unstructured":"Douglass, C. H. et al. Pathways to ensure universal and affordable access to hepatitis C treatment. BMC Med. 16, 175 (2018).","journal-title":"BMC Med."},{"key":"1174_CR121","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1111\/joim.12740","volume":"283","author":"S Olafsson","year":"2018","unstructured":"Olafsson, S. et al. Treatment as prevention for hepatitis C (TraP Hep C) \u2014 a nationwide elimination programme in Iceland using direct-acting antiviral agents. J. Intern. Med. 283, 500\u2013507 (2018).","journal-title":"J. Intern. Med."},{"key":"1174_CR122","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1093\/cid\/ciab405","volume":"74","author":"M Toy","year":"2022","unstructured":"Toy, M. et al. Cost-effectiveness of 1-time universal screening for chronic hepatitis B infection in adults in the United States. Clin. Infect. Dis. 74, 210\u2013217 (2022).","journal-title":"Clin. Infect. Dis."},{"key":"1174_CR123","doi-asserted-by":"publisher","first-page":"164","DOI":"10.3350\/cmh.2021.0193","volume":"28","author":"HW Lee","year":"2022","unstructured":"Lee, H. W. et al. Cost-effectiveness of chronic hepatitis C screening and treatment. Clin. Mol. Hepatol. 28, 164\u2013173 (2022).","journal-title":"Clin. Mol. Hepatol."},{"key":"1174_CR124","doi-asserted-by":"publisher","DOI":"10.33590\/emjhepatol\/21-00217","author":"P Berry","year":"2022","unstructured":"Berry, P. & Kotha, S. Editor\u2019s pick: the challenging ethical landscape of non-alcoholic fatty liver disease. EMJ Hepatol. https:\/\/doi.org\/10.33590\/emjhepatol\/21-00217 (2022).","journal-title":"EMJ Hepatol."},{"key":"1174_CR125","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1038\/s41591-025-03759-8","volume":"31","author":"JV Lazarus","year":"2025","unstructured":"Lazarus, J. V. et al. The people-first liver charter. Nat. Med. 31, 2109\u20132116 (2025).","journal-title":"Nat. Med."},{"key":"1174_CR126","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/liv.14360","volume":"40","author":"G Bern\u00e1","year":"2020","unstructured":"Bern\u00e1, G. & Romero-G\u00f3mez, M. The role of nutrition in non-alcoholic fatty liver disease: pathophysiology and management. Liver Int. 40, 101\u2013108 (2020).","journal-title":"Liver Int."},{"key":"1174_CR127","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1097\/MCG.0000000000001741","volume":"57","author":"EB Tapper","year":"2023","unstructured":"Tapper, E. B., Mehta, M. & Leung, C. W. Food insecurity is associated with chronic liver disease among US adults. J. Clin. Gastroenterol. 57, 737\u2013774 (2023).","journal-title":"J. Clin. Gastroenterol."},{"key":"1174_CR128","doi-asserted-by":"publisher","DOI":"10.3390\/nu17030472","volume":"17","author":"S Garc\u00eda","year":"2025","unstructured":"Garc\u00eda, S. et al. Ultra-processed food consumption and metabolic-dysfunction-associated steatotic liver disease (MASLD): a longitudinal and sustainable analysis. Nutrients. 17, 472 (2025).","journal-title":"Nutrients."},{"key":"1174_CR129","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/s41575-024-00959-4","volume":"2","author":"S Zelber-Sagi","year":"2024","unstructured":"Zelber-Sagi, S. et al. Food inequity and insecurity and MASLD: burden, challenges, and interventions. Nat Rev Gastro Hep 2, 668\u2013686 (2024).","journal-title":"Nat Rev Gastro Hep"},{"key":"1174_CR130","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1016\/S0140-6736(23)00013-2","volume":"40","author":"AB Gilmore","year":"2023","unstructured":"Gilmore, A. B. et al. Defining and conceptualising the commercial determinants of health. Lancet 40, 1194\u20131213 (2023).","journal-title":"Lancet"},{"key":"1174_CR131","doi-asserted-by":"publisher","first-page":"2703","DOI":"10.1016\/S0140-6736(25)01567-3","volume":"406","author":"P Baker","year":"2025","unstructured":"Baker, P. et al. Towards unified global action on ultra-processed foods: understanding commercial determinants, countering corporate power, and mobilising a public health response. Lancet. 406, 2703\u20132726 (2025).","journal-title":"Lancet."},{"key":"1174_CR132","first-page":"37","volume":"40","author":"C Hawkes","year":"2013","unstructured":"Hawkes, C. et al. Identifying effective food systems solutions for nutrition and noncommunicable diseases: creating policy coherence in the fats supply chain. SCN News 40, 37\u201345 (2013).","journal-title":"SCN News"},{"key":"1174_CR133","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s13679-023-00524-1","volume":"12","author":"S Vandevijvere","year":"2023","unstructured":"Vandevijvere, S. et al. Upstream determinants of overweight and obesity in Europe. Curr. Obes. Rep. 12, 417\u2013428 (2023).","journal-title":"Curr. Obes. Rep."},{"key":"1174_CR134","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/ejcn.2016.234","volume":"71","author":"L Hyseni","year":"2017","unstructured":"Hyseni, L. et al. The effects of policy actions to improve population dietary patterns and prevent diet-related non-communicable diseases: scoping review. Eur. J. Clin. Nutr. 71, 694\u2013711 (2017).","journal-title":"Eur. J. Clin. Nutr."},{"key":"1174_CR135","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph182111246","volume":"18","author":"A Weimann","year":"2021","unstructured":"Weimann, A. et al. Intersectoral action for addressing NCDs through the food environment: an analysis of NCD framing in global policies and its relevance for the African context. Int. J. Environ. Res. Public Health 18, 11246 (2021).","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"1174_CR136","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1097\/HEP.0000000000000361","volume":"78","author":"JV Lazarus","year":"2023","unstructured":"Lazarus, J. V. et al. The global fatty liver disease sustainable development goal country score for 195 countries and territories. Hepatology 78, 911\u2013928 (2023).","journal-title":"Hepatology"},{"key":"1174_CR137","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-11-160","volume":"11","author":"PO Coffin","year":"2011","unstructured":"Coffin, P. O., Stevens, A. M., Scott, J. D., Stekler, J. D. & Golden, M. R. Patient acceptance of universal screening for hepatitis C virus infection. BMC Infect. Dis. 11, 160 (2011).","journal-title":"BMC Infect. Dis."},{"key":"1174_CR138","unstructured":"O\u2019Neill Institute for National and Global Health Law. The Criminalization of Viral Hepatitis. Hepatitis Policy Project https:\/\/oneill.law.georgetown.edu\/projects\/hepatitis-policy-project\/ (O\u2019Neill Institute for National and Global Health Law, 2018)."},{"key":"1174_CR139","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41591-019-0706-x","volume":"26","author":"G Dore","year":"2020","unstructured":"Dore, G., Martinello, M., Alavi, M. & Grebely, J. Global elimination of hepatitis C virus by 2030: why not? Nat. Med. 26, 157\u2013160 (2020).","journal-title":"Nat. Med."},{"key":"1174_CR140","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1055\/s-0038-1666841","volume":"38","author":"JV Lazarus","year":"2018","unstructured":"Lazarus, J. V. et al. The micro-elimination approach to eliminating hepatitis C: strategic and operational considerations. Semin. Liver Dis. 38, 181\u2013192 (2018).","journal-title":"Semin. Liver Dis."},{"key":"1174_CR141","doi-asserted-by":"publisher","first-page":"S168","DOI":"10.1093\/infdis\/jiac446","volume":"228","author":"C-F Huang","year":"2023","unstructured":"Huang, C.-F. et al. HCV microelimination for high-risk special populations. J. Infect. Dis. 228, S168\u2013S179 (2023).","journal-title":"J. Infect. Dis."},{"key":"1174_CR142","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1055\/a-1777-6112","volume":"42","author":"JV Lazarus","year":"2022","unstructured":"Lazarus, J. V. A global systematic review of hepatitis C elimination efforts through micro-elimination. Semin Liver Dis. 42, 159\u2013172 (2022).","journal-title":"Semin Liver Dis."},{"key":"1174_CR143","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2020.11.001","volume":"45","author":"JV Lazarus","year":"2021","unstructured":"Lazarus, J. V. et al. Hepatitis C standards of care: a review of good practices since the advent of direct-acting antiviral therapy. Clin. Res. Hepatol. Gastroenterol. 45, 101564 (2021).","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"1174_CR144","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1097\/HEP.0000000000000545","volume":"79","author":"JV Lazarus","year":"2024","unstructured":"Lazarus, J. V. et al. A global action agenda for turning the tide on fatty liver disease. Hepatology. 79, 502\u2013523 (2024).","journal-title":"Hepatology."},{"key":"1174_CR145","unstructured":"World Health Organization. Global Health Sector Strategy on Viral Hepatitis 2016\u20132021: Towards Ending Viral Hepatitis (WHO, 2016)."},{"key":"1174_CR146","unstructured":"World Health Organization. Strengthening Prevention, Control and Elimination of Mmalaria and Neglected Tropical Diseases: WHA75.20 (WHO, 2022)."},{"key":"1174_CR147","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1111\/liv.15843","volume":"44","author":"A Kandeel","year":"2024","unstructured":"Kandeel, A. et al. Evidence for the elimination of viral hepatitis B and C in Egypt: results of a nationwide survey in 2022. Liver Int. 44, 955\u2013965 (2024).","journal-title":"Liver Int."},{"key":"1174_CR148","unstructured":"UHC2030. 2024\u20132027 Strategic Framework (UHC2030, 2024)."},{"key":"1174_CR149","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/S0140-6736(23)01174-1","volume":"402","author":"M Serra-Burriel","year":"2023","unstructured":"Serra-Burriel, M. et al. Development, validation, and prognostic evaluation of a risk score for long-term liver-related outcomes in the general population: a multicohort study. Lancet. 402, 988\u2013996 (2023).","journal-title":"Lancet."},{"key":"1174_CR150","doi-asserted-by":"publisher","first-page":"5715","DOI":"10.3748\/wjg.v27.i34.5715","volume":"27","author":"W Liu","year":"2021","unstructured":"Liu, W. et al. Artificial intelligence for hepatitis evaluation. World J. Gastroenterol. 27, 5715\u20135726 (2021).","journal-title":"World J. Gastroenterol."},{"key":"1174_CR151","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.cld.2023.01.021","volume":"27","author":"JV Lazarus","year":"2023","unstructured":"Lazarus, J. V. et al. Physicians\u2019 use of digital health interventions in the management of nonalcoholic fatty liver disease. Clin. Liver Dis. 27, 515\u2013533 (2023).","journal-title":"Clin. Liver Dis."},{"key":"1174_CR152","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pdig.0000651","volume":"3","author":"JL Cross","year":"2024","unstructured":"Cross, J. L., Choma, M. A. & Onofrey, J. A. Bias in medical AI: implications for clinical decision-making. PLoS Digit. Health 3, e0000651 (2024).","journal-title":"PLoS Digit. Health"},{"key":"1174_CR153","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-025-01790-0","volume":"8","author":"A Mahajan","year":"2025","unstructured":"Mahajan, A., Obermeyer, Z., Daneshjou, R., Lester, J. & Powell, D. Cognitive bias in clinical large language models. NPJ Digit. Med. 8, 428 (2025).","journal-title":"NPJ Digit. Med."},{"key":"1174_CR154","unstructured":"European Parliament. EU AI Act: First Regulation on Artificial Intelligence https:\/\/www.europarl.europa.eu\/topics\/en\/article\/20230601STO93804\/eu-ai-act-first-regulation-on-artificial-intelligence (European Union, 2025)."},{"key":"1174_CR155","first-page":"24","volume":"25","author":"A Park","year":"2018","unstructured":"Park, A. et al. Screening and treating hepatitis C in the VA: achieving excellence using lean and system redesign. Fed. Pract. 25, 24\u201329 (2018).","journal-title":"Fed. Pract."},{"key":"1174_CR156","doi-asserted-by":"publisher","first-page":"349","DOI":"10.7326\/0003-4819-159-5-201309030-00672","volume":"159","author":"VA Moyer","year":"2013","unstructured":"Moyer, V. A. et al. Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement. Ann. Intern. Med. 159, 349\u2013257 (2013).","journal-title":"Ann. Intern. Med."},{"key":"1174_CR157","first-page":"1","volume":"61","author":"BD Smith","year":"2012","unstructured":"Smith, B. D. et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm. Rep. 61, 1\u201332 (2012).","journal-title":"MMWR Recomm. Rep."}],"container-title":["Nature Reviews Gastroenterology & Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41575-026-01174-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41575-026-01174-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41575-026-01174-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:01:57Z","timestamp":1774915317000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41575-026-01174-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":157,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1174"],"URL":"https:\/\/doi.org\/10.1038\/s41575-026-01174-z","relation":{},"ISSN":["1759-5045","1759-5053"],"issn-type":[{"value":"1759-5045","type":"print"},{"value":"1759-5053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,30]]},"assertion":[{"value":"15 January 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors acknowledge that papers authored by scholars from historically excluded groups are systematically under-cited. Every attempt has been made to reference relevant papers in a manner that is equitable in terms of racial, ethnic, gender and geographical representation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Citation diversity statement"}}]}}